OverviewSuggest Edit

Osmotica Pharmaceutical is a fully-integrated pharmaceutical company specializing in osmotic drug delivery. The Company possesses a diversified product portfolio in the specialty neurology and women's health space, including five promoted products and approximately 35 non-promoted products, several of which incorporate the proprietary Osmodex® drug delivery system. The non-promoted product portfolio includes methylphenidate HCl ER tablets and venlafaxine HCl ER tablets and prescription and non-prescription dietary supplements.

TypePublic
Founded2000
HQBridgewater, NJ, US
Websiteosmotica.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2018)466(+13%)
Revenue (FY, 2019)$240 M(-8%)
Share Price (Jan 2021)$4.5 (+5%)
Cybersecurity ratingAMore

Key People/Management at Osmotica Pharmaceuticals

David Burgstahler

David Burgstahler

Director
Brian Markison

Brian Markison

Chairman of the Board and Chief Executive Officer
Sriram Venkataraman

Sriram Venkataraman

Director
Tina Devries

Tina Devries

EVP, Research and Development
Joachim Benes

Joachim Benes

Director
Andrew Einhorn

Andrew Einhorn

Chief Financial Officer
Show more

Osmotica Pharmaceuticals Office Locations

Osmotica Pharmaceuticals has offices in Bridgewater, Marietta, Sayreville, Tampa and in 4 other locations
Bridgewater, NJ, US (HQ)
400 Crossing Blvd
Marietta, GA, US
895 Sawyer Rd
Sayreville, NJ, US
2500 Main Street Extension #6
Tampa, FL, US
2631 Causeway Center Dr
Wilmington, NC, US
1904 Eastwood Rd STE 205
Almagro, AR
821 Francisco Acuña de Figueroa
Show all (8)

Osmotica Pharmaceuticals Financials and Metrics

Osmotica Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Osmotica Pharmaceuticals's revenue was reported to be $240.03 m in FY, 2019
USD

Revenue (Q2, 2020)

37.5m

Gross profit (Q2, 2020)

17.5m

Gross profit margin (Q2, 2020), %

46.7%

Net income (Q2, 2020)

(13.0m)

EBIT (Q2, 2020)

(8.4m)

Market capitalization (22-Jan-2021)

279.1m

Closing stock price (22-Jan-2021)

4.5

Cash (30-Jun-2020)

140.4m

EV

411.1m
Osmotica Pharmaceuticals's current market capitalization is $279.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

170.5m237.7m263.7m240.0m

Revenue growth, %

39%

Cost of goods sold

125.6m125.2m135.0m111.6m

Gross profit

44.9m112.5m128.7m128.4m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

53.7m66.3m57.1m57.5m65.5m48.6m37.5m

Cost of goods sold

21.5m32.0m29.2m32.6m27.3m20.6m20.0m

Gross profit

32.3m34.3m27.9m24.9m38.1m28.1m17.5m

Gross profit Margin, %

60%52%49%43%58%58%47%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

19.6m34.7m70.8m95.9m

Accounts Receivable

43.7m37.6m56.4m43.9m

Prepaid Expenses

9.5m25.8m20.7m11.5m

Inventories

19.8m17.0m24.4m21.3m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

32.2m63.1m63.7m98.0m125.8m140.4m

Accounts Receivable

72.7m56.9m68.1m33.9m32.6m17.0m

Prepaid Expenses

18.8m16.2m14.2m8.2m10.7m9.1m

Inventories

25.6m27.8m27.9m27.2m20.5m20.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(41.8m)(45.2m)(109.4m)(270.9m)

Depreciation and Amortization

23.6m46.5m81.6m57.0m

Inventories

12.6m2.9m(7.4m)3.1m

Accounts Payable

(14.4m)588.2k(11.3m)(16.4m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(42.3m)(3.6m)(6.2m)(130.9m)(244.3m)(3.1m)(16.1m)

Depreciation and Amortization

24.9m61.3m18.0m36.0m50.6m5.6m11.2m

Inventories

(132.9k)(8.6m)(3.4m)(3.5m)(2.9m)769.0k1.0m

Accounts Payable

(21.8m)(9.1m)(4.3m)(6.0m)(15.0m)289.0k304.0k
USDFY, 2016

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x
Show all financial metrics

Osmotica Pharmaceuticals Operating Metrics

Oct, 2018

Products

35
Show all operating metrics

Osmotica Pharmaceuticals Revenue Breakdown

Embed Graph

Osmotica Pharmaceuticals revenue breakdown by business segment: 9.4% from Lorzone, 7.8% from Divigel, 40.4% from Venlafaxine ER, 18.4% from Methylphenidate and 24.0% from Other

Osmotica Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Osmotica Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Osmotica Pharmaceuticals Online and Social Media Presence

Embed Graph

Osmotica Pharmaceuticals News and Updates

Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets

BRIDGEWATER, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeki…

Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas

Adamas to acquire global rights to OSMOLEX ER® for $7.5 million

Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at t…

Osmotica Pharmaceuticals plc to Provide Third Quarter 2020 Business and Financial Update on November 10, 2020

BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 third quarter financial results on Tuesday, November 10, 2020, after …

Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020

-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- -Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO-

Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults

-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and commercial plans --
Show more

Osmotica Pharmaceuticals Frequently Asked Questions

  • When was Osmotica Pharmaceuticals founded?

    Osmotica Pharmaceuticals was founded in 2000.

  • Who are Osmotica Pharmaceuticals key executives?

    Osmotica Pharmaceuticals's key executives are David Burgstahler, Brian Markison and Sriram Venkataraman.

  • How many employees does Osmotica Pharmaceuticals have?

    Osmotica Pharmaceuticals has 466 employees.

  • What is Osmotica Pharmaceuticals revenue?

    Latest Osmotica Pharmaceuticals annual revenue is $240 m.

  • What is Osmotica Pharmaceuticals revenue per employee?

    Latest Osmotica Pharmaceuticals revenue per employee is $515.1 k.

  • Who are Osmotica Pharmaceuticals competitors?

    Competitors of Osmotica Pharmaceuticals include Opiant Pharmaceuticals, Adamas Pharmaceuticals and IntelGenx.

  • Where is Osmotica Pharmaceuticals headquarters?

    Osmotica Pharmaceuticals headquarters is located at 400 Crossing Blvd, Bridgewater.

  • Where are Osmotica Pharmaceuticals offices?

    Osmotica Pharmaceuticals has offices in Bridgewater, Marietta, Sayreville, Tampa and in 4 other locations.

  • How many offices does Osmotica Pharmaceuticals have?

    Osmotica Pharmaceuticals has 8 offices.